SCHEMBL6799992

SCHEMBL6799992

CC(C)(C)OC(=O)NC1CCN(c2cc3c(cc2F)c(=O)n(O)c(=O)n3-c2ccc(F)cc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.42
PIM3 Q86V86 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
F10 P00742 1/20 0.41
KDM4D Q6B0I6 3/20 0.41
BRD4 O60885 1/20 0.38
DGAT2 Q96PD7 2/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
OGFRL1 Q5TC84 1/20 0.37
USP14 P54578 1/20 0.37
SUV39H2 Q9H5I1 3/20 0.37
PDE10A Q9Y233 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
PLK1 P53350 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795146 0.93 PIM1 (0.41) PIM1PIM3PIM2F10OPRM1
SCHEMBL6801118 0.88 MTNR1A (0.45) PIM1PIM3PIM2F10BRD4
SCHEMBL6801123 0.86 PIM1 (0.41) PIM1PIM3PIM2F10KDM4D
SCHEMBL6802963 0.79 PIM1 (0.40) PIM1PIM3PIM2F10OPRM1
SCHEMBL6797144 0.79 PRKD3 (0.45) PIM1PIM3F10OPRM1OPRD1
SCHEMBL6794974 0.79 PIM1 (0.40) PIM1PIM3PIM2F10BRD4
SCHEMBL8151182 0.78 PIM1 (0.41) PIM1PIM3PIM2F10KDM4D
SCHEMBL4524232 0.78 PIM1 (0.42) PIM1PIM3PIM2F10KDM4D
SCHEMBL4510547 0.78 PIM1 (0.42) PIM1PIM3PIM2F10KDM4D
Hydrochloric Acid SCHEMBL7006179 0.78 PRKD3 (0.44) PIM1PIM3F10OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed
EP-1028950-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 2000-08-23 EP disclosed
WO-1999021840-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A PIM1 2808/4885PIM3 2414/4885PIM2 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.